Nektar to sell Huntsville PEGylation plant to Ampersand for $90M

NEKTAR THERAPEUTICS

Total consideration $90M ($70M cash, $20M equity in new Ampersand portfolio co.).
Expected close by Dec 2, 2024; all Huntsville employees offered jobs at new co.
Nektar retains existing royalty/milestone rights; enters supply agreements for PEG reagents.
Sale not subject to financing; extends Nektar cash runway into Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.